- Home
- YORW vs SEPN Comparison
YORW vs SEPN Comparison
Compare YORW & SEPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YORW
- SEPN
- Stock Information
- Founded
- YORW 1816
- SEPN 2022
- Country
- YORW United States
- SEPN United States
- Employees
- YORW N/A
- SEPN N/A
- Industry
- YORW Water Supply
- SEPN
- Sector
- YORW Utilities
- SEPN
- Exchange
- YORW Nasdaq
- SEPN NYSE
- Market Cap
- YORW 481.3M
- SEPN 453.2M
- IPO Year
- YORW N/A
- SEPN 2024
- Fundamental
- Price
- YORW $31.76
- SEPN $10.73
- Analyst Decision
- YORW
- SEPN Strong Buy
- Analyst Count
- YORW 0
- SEPN 5
- Target Price
- YORW N/A
- SEPN $26.75
- AVG Volume (30 Days)
- YORW 83.2K
- SEPN 520.0K
- Earning Date
- YORW 08-01-2025
- SEPN 08-15-2025
- Dividend Yield
- YORW 2.76%
- SEPN N/A
- EPS Growth
- YORW N/A
- SEPN N/A
- EPS
- YORW 1.37
- SEPN N/A
- Revenue
- YORW $75,787,000.00
- SEPN $977,000.00
- Revenue This Year
- YORW $7.50
- SEPN N/A
- Revenue Next Year
- YORW $6.33
- SEPN $526.96
- P/E Ratio
- YORW $23.24
- SEPN N/A
- Revenue Growth
- YORW 3.45
- SEPN 108.76
- 52 Week Low
- YORW $29.86
- SEPN $4.17
- 52 Week High
- YORW $41.96
- SEPN $28.99
- Technical
- Relative Strength Index (RSI)
- YORW 41.88
- SEPN N/A
- Support Level
- YORW $31.64
- SEPN N/A
- Resistance Level
- YORW $32.95
- SEPN N/A
- Average True Range (ATR)
- YORW 0.61
- SEPN 0.00
- MACD
- YORW 0.05
- SEPN 0.00
- Stochastic Oscillator
- YORW 18.56
- SEPN 0.00
About YORW York Water Company (The)
The York Water Co is an investor-owned water utility company in the United States. The primary business of the company is to impound, purify to meet or exceed safe drinking water standards and distribute water. It also owns and operates three wastewater collection systems and eleven wastewater collection and treatment systems. The company operates within its franchised territory, which covers more than 57 municipalities within four counties in south-central Pennsylvania.
About SEPN SEPTERNA INC
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.